MAPT and Alzheimer disease: Early-onset AD (EOAD), presenting before the age of 65, has been observed to be a ‘purer’ form of the disease, with early-onset patients having a higher tau burden and fewer co-pathologies than late-onset patients.10-13 Therefore, investigating inflammation in a cohort of EOAD patients could help elucidate more clearly the relationship between brain inflammation and the build-up of Aβ and hyperphosphorylated tau.